2,510 Shares in IQVIA Holdings Inc. $IQV Bought by Algert Global LLC

Key Points

• Algert Global LLC has acquired a new position in IQVIA Holdings Inc., purchasing 2,510 shares valued at approximately $443,000 in Q1, contributing to the 89.62% ownership by institutional investors.
• Analysts have upgraded their price targets for IQVIA, with UBS Group raising it from $185.00 to $225.00 and Truist Financial from $209.00 to $235.00, indicating strong confidence in the company's stock performance.
• IQVIA reported earnings of $2.81 per share for the last quarter, surpassing expectations, and expects a fiscal year 2025 EPS guidance of 11.750-12.050.

Algert Global LLC acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 2,510 shares of the medical research company's stock, valued at approximately $443,000.

Several other institutional investors also recently modified their holdings of the business. Continuum Advisory LLC grew its position in shares of IQVIA by 3.7% during the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock worth $354,000 after buying an additional 64 shares during the period. Ballentine Partners LLC grew its position in shares of IQVIA by 4.9% during the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock worth $260,000 after buying an additional 69 shares during the period. Independent Advisor Alliance grew its position in shares of IQVIA by 4.2% during the 1st quarter. Independent Advisor Alliance now owns 1,801 shares of the medical research company's stock worth $318,000 after buying an additional 72 shares during the period. ST Germain D J Co. Inc. grew its position in shares of IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares during the period. Finally, Nemes Rush Group LLC grew its position in shares of IQVIA by 15.0% during the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock worth $109,000 after buying an additional 81 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

IQV has been the topic of several recent analyst reports. William Blair reissued an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Truist Financial lifted their price objective on shares of IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Redburn Partners set a $188.00 price objective on shares of IQVIA in a research note on Friday, May 23rd. Barclays lifted their price objective on shares of IQVIA from $165.00 to $185.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 23rd. Finally, Mizuho lifted their price objective on shares of IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $228.62.

Insiders Place Their Bets

In other news, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the sale, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. The trade was a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

IQVIA Stock Down 0.0%

IQV traded down $0.07 during trading on Thursday, reaching $188.73. The company had a trading volume of 1,161,570 shares, compared to its average volume of 1,946,132. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $252.88. The business's fifty day moving average price is $175.64 and its 200 day moving average price is $168.11. The company has a market cap of $32.08 billion, a P/E ratio of 27.31, a PEG ratio of 2.06 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the previous year, the firm posted $2.64 earnings per share. The business's revenue was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.